Clinical Trials Browser

Phase 2 × Interventional × amivantamab × Clear all

NCT07042295 2026-04-17

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

Phase 2 Recruiting

Locally Recurrent Skin Squamous Cell Carcinoma

NCT05498428 2026-04-13

PALOMA-2

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05663866 2026-04-13

Premedication to Reduce Amivantamab Associated Infusion Related Reactions

Phase 2 Active not recruiting

68 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT06120140 2026-04-13

COCOON

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06667076 2026-04-13

COPERNICUS

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05801029 2026-03-20

OSTARA

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05845450 2026-03-12

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT05117931 2026-02-17

A Study of Amivantamab in People With Esophagogastric Cancer

Phase 2 Active not recruiting

Neoplasm Metastasis

NCT07392658 2026-02-06

AMICUTE

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05601973 2026-01-21

AMAZE-lung

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04965090 2025-12-18

A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung

NCT06116682 2025-12-05

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05299125 2025-10-01

AMIGO-1

Phase 2 Active not recruiting

Metastatic Non-small Cell Lung Cancers

NCT05074940 2025-04-10

Amivantamab in Adenoid Cystic Carcinoma

Phase 2 Active not recruiting

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

NCT06855849 2025-03-04

An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.

Phase 2 Not yet recruiting

Gastrointestinal

RAS/BRAF Wild-type Advanced Colorectal Cancer Patients

NCT05653427 2025-01-13

A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma

Phase 2 Terminated

18 enrolled 20 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT04945733 2024-09-19

A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer

Phase 2 Terminated

62 enrolled 28 charts

Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

NCT03767075 2024-04-25

BoB

Phase 2 Recruiting

Neoplasms